title: High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance.
abstract: Although amiodarone is an effective drug for the treatment of life-threatening ventricular arrhythmias, no standard oral loading dose protocol has been defined, and patients often undergo prolonged hospitalization for amiodarone loading. High dose (greater than 1,800 mg/day) oral loading has usually been reserved for unstable patients with incessant ventricular tachyarrhythmias. The current study was designed to 1) examine the clinical and electrophysiologic effects of a high dose oral amiodarone loading regimen in more stable patients; and 2) ascertain its safety and tolerance, possibly allowing shortened amiodarone loading periods and potentially decreased length of hospital stay. The study group included 16 patients with a history of recurrent ventricular arrhythmias and decreased left ventricular function, who were refractory to prior antiarrhythmic drug therapy. The oral loading protocol was 50 mg/kg per day of amiodarone for 3 days, then 30 mg/kg per day for 2 days, followed by maintenance therapy of 300 to 400 mg twice daily. Electrophysiologic testing was performed at baseline, on days 1 and 5 and during week 6. Amiodarone and desethylamiodarone levels were measured and symptoms monitored. Clinically, the high dose loading protocol was well tolerated in 15 of the 16 patients. Arrhythmias were rendered noninducible by day 1 in three patients and remained noninducible throughout the study period in two of the three. The remaining patients continued to have inducible ventricular tachycardia. Ventricular tachycardia cycle length and right ventricular effective refractory period both progressively increased significantly over baseline, starting on day 1. The 15 patients who remained in the study had no significant side effects during the loading period.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles 90048.
authors.forename: S J
authors.initials: SJ
authors.lastname: Evans
authors.forename: M
authors.initials: M
authors.lastname: Myers
authors.forename: C
authors.initials: C
authors.lastname: Zaher
authors.forename: J
authors.initials: J
authors.lastname: Simonson
authors.forename: P
authors.initials: P
authors.lastname: Nalos
authors.forename: C
authors.initials: C
authors.lastname: Vaughn
authors.forename: D
authors.initials: D
authors.lastname: Oseran
authors.forename: E
authors.initials: E
authors.lastname: Gang
authors.forename: T
authors.initials: T
authors.lastname: Peter
authors.forename: W
authors.initials: W
authors.lastname: Mandel
mesh_terms: D000284:Administration, Oral; D000638:Amiodarone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004361:Drug Tolerance; D004594:Electrophysiology; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D012008:Recurrence; D013610:Tachycardia / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors
chemical_list: C036116:desethylamiodarone; D000638:Amiodarone